If the end of infusion is delayed beyond th e nominal infusion duration, the collection of this sample should a lso be delayed accordingly. EOI samples may not be collected from the same IV access as the drug was administered. cSamples will be taken as directed when drug-related adverse event, Grade 3/4 infusion reaction, or hypersensitivity reaction is confirmed. Abbreviations: C = Cycle; D = Day; EOI = end of infusion; EOT = end of treatment; FU = follow-up Revised Protocol No.: 04 Date: 31-May-2019 120 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS The serum samples will be analyzed for drug (BMS-986226 ) and ADA (BMS-986226 antibodies and/or anti-nivolumab or anti-ipilimumab antibodies) by validated immunoassays. Serum samples designated for PK assessments may also be used for immunogenicity analysis if required (eg, insufficient volume for complete immunogenicit y assessment or to follow up on suspected immunogenicity related AEs).